Registration
08.30 - 08.55
Welcome address
08.55 - 09.00
Session 1: Tumor Immunity and Immunomodulation
Unraveling the role of oncogenes and tumor suppressor genes as a tool for immune evasion
09.00 - 09.30
Germany
Understanding the inflammatory infiltrate in common solid cancers
09.30 - 10.00
Greece
Coffee Break
11.00 - 11.30
Keynote Lecture
Session 2: Cancer Vaccines
Targeting Mutated GNAS for Treatment of Pseudomyxoma peritonei
12.15 - 12.45
Norway
Personal Vaccines Targeting Neoantigens in Patients with Melanoma and other Solid Tumors
13.15 - 13.45
Lunch Break
14.15 - 15.15
Short Presentations
15.15 - 16.30
TCR REPERTOIRE AND IMMUNE-RELATED GENES AS PUTATIVE BIOMARKERS IN HEAD AND NECK CANCER
15:15 - 15:25
Greece
IMMUNE-GENE EXPRESSION AND TCR CLONOTYPES IN TUMOR MICROENVIRONMENT AND PERIPHERAL BLOOD IMMUNE CELLS IN HEAD AND NECK CANCER
15.25 -15.35
DIFFERENTIALLY EXPRESSED GENES AMONG HPV-POSITIVE AND HPV-NEGATIVE HEAD AND NECK CANCER PATIENTS
15.35 - 15.45
Greece
PRE-EXISTING CANCER-ANTIGEN SPECIFIC CD8+ T-CELLS AS A PREDICTIVE BIOMARKER FOR IMMUNOTHERAPY IN NSCLC PATIENTS
15.45 - 15.55
Greece
ALTERATIONS IN THE TCR Vβ REPERTOIRE COMPOSITION OF NON-SMALL CELL LUNG CANCER PATIENTS AFTER IMMUNOTHERAPY
15.55 - 16.05
Greece
BELANTAMAB MAFODOTIN INDUCES THE ICD OF MYELOMA CELLS IN MULTIPLE MYELOMA PATIENTS
16.05 - 16.15
Greece
Q & A
16.15 - 16.30
Session 3: Skin Neoplasms and Head and Neck Cancer - Current Status of Immunotherapy and Future Perspectives
16.30 - 18.00
Coffee Break
18.00-18.30
Keynote Lecture
Session 4: Cancer Biomarkers and Advances in Cancer Treatments
Discovery and validation of Treg-oriented immune checkpoints for cancer immunotherapy
10.00-10.30
France
Coffee Break
11.00-11.30
Keynote Lecture
Session 5: Advances in Anti-cancer Immunotherapeutic Approaches
Complement therapeutics and their prospects for cancer immunotherapy
13.15-13.45
Greece
Light Lunch
14.15-15.15
Short Presentations
PRECLINICAL STUDY OF PHAGE-BASED VACCINES INDUCING THERAPEUTIC IMMUNITY AGAINST Δ16HER2-DRIVEN MAMMARY TUMORIGENESIS
15.15-15.25
Italy
TARGETING MUTANT P53 IN SPONTANEOUS CANCER BY T CELL RECEPTOR GENE THERAPY
15.35-15.45
Germany
RADIOTHERAPY, HLA-CLASS-I MOLECULES AND IFN-TYPE-I RESPONSE IN COLORECTAL CANCER CELL LINES
15.45-15.55
Greece
IFNγ, HIF1α AND PD-L1 EXPRESSION IN PROSTATE ANDROGEN-DEPENDENT AND INDEPENDENT CANCER CELL LINES
15.55 - 16.05
Greece
Q & A
16.05 - 16.30
Coffee Break
16.30 - 17.00
Session 6: Current Status of Immunotherapy and Future Perspectives in Selective Cancer
Immune Checkpoint Inhibitors in mismatch repair deficient solid tumors: current knowledge and future directions, an expert opinion - Sponsored by GSK
17.30-18.00
France
Coffee Break
18:00 - 18:15
Keynote Lecture
Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer
18:15 - 19.00
Session 7: Urinary Tract Neoplasms: Current Challenges and Future Perspectives
19:00-20:00
Session 8: Intrinsic Regulation of Antitumor Immune Responses
IL-37: an immunoregulatory cytokine with a potential pathogenetic role in human cancers
09.00-09.30
Cyprus
The role of chromosomal aberrations in melanoma resistance to immunotherapy
11.00-11.30
Germany
Coffee Break
11.30-12.00
Keynote Lecture
Beyond CAR-T Cells a novel approach to develop off the shelf iPSC CAR-NK cells
12.00-12.45
Session 9: Extrinsic Regulation of Antitumor Immune Responses
Cancer Immuno-Radiotherapy: Balancing between immunosuppression and radio-vaccination
12.45-13.15
Greece
Epithelial Toll-like receptor-2 as a regulator of intestinal epithelial renewal and its role in colorectal cancer
13.15-13.45
Germany
Immunotherapy- induced alterations in the TCR Vβ repertoire of non-small cell lung cancer patients
13.45-14.15
Greece
Lunch Break
14.15-15.15
Short Presentations
15.15-16.30
ASSESSING MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA WITH NEXT-GENERATION FLOW CYTOMETRY: A REPORT OF INTERESTING CASES
15:25-15:35
Greece
IMMUNOPHENOTYPIC COMPARISON OF HUMAN AND CANINE LYMPHOMAS WITH FLOW CYTOMETRY
15.35-15.45
Greece
STUDY OF THE ANTI-NEOPLASTIC ACTIVITY OF OLEUROPEIN ANALOGUES IN VITRO
15.45-15.55
Greece
IN VIVO INVESTIGATION OF THE ANTI-CANCER ACTIVITY OF GS32, A NOVEL SEMI-SYNTHETIC ANALOGUE OF OLEUROPEIN
15.55-16.05
Greece
Q & A
16.05-16.30
Session 10: Immunotherapy in Lung Cancer: Current Challenges and Future Perspectives
The value of the immunotherapy in SCLC treatment: meeting the expectations - Sponsored by ASTRA ZENECA
16.30-17.00
Spain
First-line treatment of NSCLC: What is the preferred regimen?
17:30-18:00
Coffee Break
18:30-18:45
Session 11: Cancer Immunotherapy in 2022 and a look ahead
Tumor-derived exosomes in plasma of cancer patients induce stress and death in immune cells: danger from within
18:45- 19:15
A renaissance for B cell immune monitoring and its perspective for tumor immunology
19:15-19:45
Abstract Awards: Organizing Committee
20:15-20:30
Concluding Remarks: Organizing Committee
20:30 - 20:45